Program
tocilizumab
Also written as “Tocilizumab”, “tocilizumab [RoActemra/Actemra]” and “MRA(Tocilizumab)”.
Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · COVID-19 · Scleroderma, Systemic · Giant Cell Arteritis, led by 9 companies.
Drug pageTocilizumab: every studyMany companies study it; this page follows only the 129 they lead. All 336 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 1162 open or running | phase 4since Nov 9, 2009 | Mar 25, 2005 | Jul 30, 2027phase 2 · NCT04524871 |
| Bio-Thera Solutionsits history only | 30 open or running | phase 3since Jan 22, 2019 | Jul 12, 2018 | none ahead |
| Bristol-Myers Squibbits history only | 22 open or running | phase 3since Jan 9, 2026 | Feb 7, 2025 | Nov 14, 2028phase 3 · NCT07335562 |
| Fresenius Kabiits history only | 20 open or running | phase 3since Aug 11, 2020 | Aug 30, 2017 | none ahead |
| JW Pharmaceuticalits history only | 20 open or running | phase 3since Sep 29, 2010 | Sep 29, 2010 | none ahead |
| Beijing VDJBioits history only | 10 open or running | phase 2since Jul 11, 2023 | Jul 11, 2023 | none ahead |
| Biogenits history only | 10 open or running | phase 1since Feb 8, 2024 | Feb 8, 2024 | none ahead |
| Celltrionits history only | 10 open or running | phase 3since Feb 2, 2023 | Feb 2, 2023 | none ahead |
| Mycenax Biotechits history only | 10 open or running | phase 1since Apr 11, 2018 | Apr 11, 2018 | none ahead |
Also a collaborator on its studies: Gilead Sciences, Pfizer, Adagene, Tempest Therapeutics, NiKang Therapeutics and Immune-Onc Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jul 30, 2012.
- Apr 19, 2019Phase 1 study in Giant Cell ArteritisHoffmann-La Roche · NCT03923738 · 24 enrolled · Switzerland
- Mar 23, 2020Phase 3 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04320615 · 452 enrolled · United States, Canada, Denmark and more
- Apr 21, 2020Phase 2 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04363736 · 97 enrolled · United States
- Apr 29, 2020Phase 3 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04372186 · 377 enrolled · United States, Brazil, Kenya and more
- May 28, 2020Phase 3 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04409262 · 649 enrolled · United States, Brazil, Russian Federation and more
- Aug 11, 2020Phase 3 study in Arthritis, RheumatoidFresenius Kabi · NCT04512001 · 604 enrolled · Bulgaria, Czechia, Georgia and more
- Aug 21, 2020Phase 2 study in Advanced Liver CancersHoffmann-La Roche · NCT04524871 · 518 enrolled · United States, China, France and more
- Dec 16, 2021Phase 1 study in COVID-19Hoffmann-La Roche · NCT05164133 · 2 enrolled · United States, Brazil, Croatia and more
- Feb 2, 2023Celltrion’s first study: phase 3 study in Arthritis, RheumatoidNew to CelltrionCelltrion · NCT05725434 · 30 enrolled
- Jul 11, 2023Beijing VDJBio’s first study: phase 2 study in Arthritis, RheumatoidNew to Beijing VDJBioBeijing VDJBio · NCT05957107 · 181 enrolled · China
- Jul 20, 2023Phase 1 study in Healthy MenBio-Thera Solutions · NCT05968508 · 300 enrolled · China
- Feb 8, 2024Biogen’s first study: phase 1 study in Healthy VolunteerNew to BiogenBiogen · NCT06262477 · 300 enrolled · United States, United Kingdom
- Feb 7, 2025Bristol-Myers Squibb’s first study: phase 1 study in Autoimmune DiseasesNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT07115745 · 125 planned · United States, Australia, Brazil and more
- Jan 9, 2026Phase 3 study in Scleroderma, SystemicPhase 3 reachedBristol-Myers Squibb · NCT07335562 · 92 planned · United States, Belgium, Canada and more
Ahead
- Jul 30, 2027Primary completion: phase 2 study in Advanced Liver CancersHoffmann-La Roche · NCT04524871
- Nov 14, 2028Primary completion: phase 3 study in Scleroderma, SystemicBristol-Myers Squibb · NCT07335562
- Mar 15, 2029Primary completion: phase 1 study in Autoimmune DiseasesBristol-Myers Squibb · NCT07115745
- Sep 30, 2030Primary completion: phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT03424005
TargetBeta
“A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity”NCIt, by rule
“Interleukin-6 receptor alpha subunit inhibitor”ChEMBL 37, by rule
Other programs on IL6R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sarilumabrule | Sanofi | phase 4 | 27 |
Studies
The newest 60 of 129 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07335562Scleroderma, Systemic · United States, Belgium, Canada and more | 3 | Not yet recruiting | Bristol-Myers Squibb | Nov 14, 2028 | 92 |
| NCT07115745Autoimmune Diseases · United States, Australia, Brazil and more | 1 | Recruiting | Bristol-Myers Squibb | Mar 15, 2029 | 125 |
| NCT06262477Healthy Volunteer · United States, United Kingdom | 1 | Completed | Biogen | Sep 25, 2024 | 300 |
| NCT05968508Healthy Men · China | 1 | Completed | Bio-Thera Solutions | Oct 8, 2024 | 300 |
| NCT05957107Arthritis, Rheumatoid · China | 2 | Completed | Beijing VDJBio | Jun 2, 2023 | 181 |
| NCT05725434Arthritis, Rheumatoid | 3 | UNKNOWN | Celltrion | Apr 1, 2023 | 30 |
| NCT05164133COVID-19 · United States, Brazil, Croatia and more | 1 | Completed | Hoffmann-La Roche | Mar 27, 2024 | 2 |
| NCT04524871Advanced Liver Cancers · United States, China, France and more | 2 | Active, not recruiting | Hoffmann-La Roche | Jul 30, 2027 | 518 |
| NCT04512001Arthritis, Rheumatoid · Bulgaria, Czechia, Georgia and more | 3 | Completed | Fresenius Kabi | Aug 31, 2021 | 604 |
| NCT04409262COVID-19 Pneumonia · United States, Brazil, Russian Federation and more | 3 | Completed | Hoffmann-La Roche | Feb 1, 2021 | 649 |
| NCT04372186COVID-19 Pneumonia · United States, Brazil, Kenya and more | 3 | Completed | Hoffmann-La Roche | Aug 18, 2020 | 377 |
| NCT04363736COVID-19 Pneumonia · United States | 2 | Completed | Hoffmann-La Roche | Aug 12, 2020 | 97 |
| NCT04320615COVID-19 Pneumonia · United States, Canada, Denmark and more | 3 | Completed | Hoffmann-La Roche | Jun 24, 2020 | 452 |
| NCT03923738Giant Cell Arteritis · Switzerland | 1 | Completed | Hoffmann-La Roche | Nov 12, 2020 | 24 |
| NCT03869190Carcinoma, Transitional Cell · United States, France, Greece and more | 2 | Terminated | Hoffmann-La Roche | Oct 8, 2025 | 272 |
| NCT03830203Arthritis, Rheumatoid · China | 3 | Completed | Bio-Thera Solutions | Jan 5, 2021 | 621 |
| NCT03606876Arthritis, Rheumatoid · China | 1 | Completed | Bio-Thera Solutions | Jul 17, 2019 | 138 |
| NCT03522012Pharmacokinetics · Australia | 1 | Completed | Mycenax Biotech | Sep 26, 2018 | 190 |
| NCT03424005Breast Neoplasms · United States, Australia, France and more | 2 | Recruiting | Hoffmann-La Roche | Sep 30, 2030 | 1,132 |
| NCT03301883Arthritis, Juvenile · China | 4 | Completed | Hoffmann-La Roche | Sep 4, 2021 | 62 |
| NCT03282851Healthy · New Zealand | 1 | Completed | Fresenius Kabi | Oct 1, 2019 | 696 |
| NCT03202368Giant Cell Arteritis · France | 3 | Completed | Hoffmann-La Roche | Aug 21, 2019 | 3 |
| NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more | 2 | Completed | Hoffmann-La Roche | Feb 27, 2025 | 341 |
| NCT03155347Arthritis, Rheumatoid · China | 3 | Completed | Hoffmann-La Roche | Aug 8, 2022 | 340 |
| NCT02682823Arthritis, Rheumatoid · United States | 4 | Completed | Hoffmann-La Roche | Jul 29, 2016 | 91 |
| NCT02678988Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Jun 2016 | 189 |
| NCT02573012Arthritis, Rheumatoid · France, Germany, Italy and more | 4 | Completed | Hoffmann-La Roche | Feb 9, 2018 | 314 |
| NCT02453256Scleroderma, Systemic · United States, Argentina, Belgium and more | 3 | Completed | Hoffmann-La Roche | Jan 15, 2018 | 212 |
| NCT02336048Leukemia, Lymphocytic, Chronic, B-Cell · Israel, Italy, Latvia and more | 1 | Terminated | Hoffmann-La Roche | Sep 21, 2018 | 38 |
| NCT02165345Arthritis, Juvenile · United States, Argentina, Australia and more | 1 | Completed | Hoffmann-La Roche | Nov 24, 2021 | 82 |
| NCT02046616Arthritis, Rheumatoid · Denmark, Finland, Norway and more | 3 | Completed | Hoffmann-La Roche | Sep 13, 2016 | 133 |
| NCT02046603Arthritis, Rheumatoid · United Kingdom | 3 | Completed | Hoffmann-La Roche | Aug 4, 2016 | 162 |
| NCT02031471Arthritis, Rheumatoid · Belgium, Luxembourg | 3 | Completed | Hoffmann-La Roche | Sep 2015 | 57 |
| NCT02011334Arthritis, Rheumatoid · Argentina, Brazil, Colombia and more | 3 | Completed | Hoffmann-La Roche | Oct 2016 | 285 |
| NCT02010216Arthritis, Rheumatoid · Kazakhstan | 4 | Completed | Hoffmann-La Roche | Jul 2010 | 23 |
| NCT02001987Arthritis, Rheumatoid · France | 3 | Completed | Hoffmann-La Roche | Dec 2015 | 139 |
| NCT01991990Healthy Volunteer · United Kingdom | 4 | Completed | Hoffmann-La Roche | Dec 2014 | 18 |
| NCT01987479Arthritis, Rheumatoid · Netherlands | 3 | Completed | Hoffmann-La Roche | May 26, 2016 | 150 |
| NCT01995201Arthritis, Rheumatoid · Ireland, Portugal, Spain | 3 | Completed | Hoffmann-La Roche | Jul 2015 | 401 |
| NCT01988012Arthritis, Rheumatoid · Israel | 3 | Completed | Hoffmann-La Roche | Jul 2015 | 100 |
| NCT01951170Arthritis, Rheumatoid · Australia | 3 | Completed | Hoffmann-La Roche | Aug 2015 | 52 |
| NCT01941940Arthritis, Rheumatoid · Italy | 3 | Completed | Hoffmann-La Roche | Sep 9, 2015 | 227 |
| NCT01941095Arthritis, Rheumatoid · Greece | 3 | Completed | Hoffmann-La Roche | Jul 10, 2016 | 100 |
| NCT01904292Arthritis, Juvenile · United States, Argentina, Australia and more | 1 | Completed | Hoffmann-La Roche | Jun 13, 2017 | 52 |
| NCT01904279Arthritis, Juvenile · United States, Argentina, Australia and more | 1 | Completed | Hoffmann-La Roche | May 2016 | 52 |
| NCT01878318Arthritis, Rheumatoid | 4 | Withdrawn | Hoffmann-La Roche | Jun 2015 | 0 |
| NCT01791153Giant Cell Arteritis · United States, Belgium, Canada and more | 3 | Completed | Hoffmann-La Roche | Apr 11, 2016 | 251 |
| NCT01772316Arthritis, Rheumatoid · Spain | 3 | Completed | Hoffmann-La Roche | May 2015 | 47 |
| NCT01734382Arthritis, Juvenile · United States, Argentina, Canada and more | 4 | Completed | Hoffmann-La Roche | Oct 9, 2019 | 35 |
| NCT01734993Arthritis, Rheumatoid · France | 3 | Completed | Hoffmann-La Roche | Sep 2015 | 11 |
| NCT01730456Arthritis, Rheumatoid · North Macedonia | 3 | Completed | Hoffmann-La Roche | May 2015 | 13 |
| NCT01727986Arthritis, Juvenile · Brazil | 3 | Completed | Hoffmann-La Roche | Nov 2015 | 11 |
| NCT01715831Arthritis, Rheumatoid · Brazil | 4 | Completed | Hoffmann-La Roche | Jun 6, 2016 | 26 |
| NCT01673919Arthritis, Juvenile · France | 3 | Completed | Hoffmann-La Roche | Jan 2014 | 7 |
| NCT01668966Arthritis, Rheumatoid · Brazil | 3 | Completed | Hoffmann-La Roche | May 11, 2016 | 23 |
| NCT01667471Arthritis, Juvenile · Germany | 3 | Completed | Hoffmann-La Roche | Aug 2013 | 6 |
| NCT01665430Arthritis, Rheumatoid · Poland | 3 | Terminated | Hoffmann-La Roche | Feb 2015 | 38 |
| NCT01664598Arthritis, Rheumatoid · Russian Federation | 3 | Completed | Hoffmann-La Roche | Jun 2015 | 49 |
| NCT01662063Arthritis, Rheumatoid · United States, Puerto Rico | 3 | Completed | Hoffmann-La Roche | Apr 2014 | 218 |
| NCT01655381Arthritis, Rheumatoid · France | 3 | Completed | Hoffmann-La Roche | Jul 2015 | 15 |
How it is read
Names in the registry
- “Tocilizumab”, 54 entries
- “tocilizumab [RoActemra/Actemra]”, 47 entries
- “MRA(Tocilizumab)”, 11 entries
- “tocilizumab”, 6 entries
- “MSB11456”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 87 studies
- Arthritis, Juvenile, 16 studies
- COVID-19, 5 studies
- Scleroderma, Systemic, 3 studies
- Giant Cell Arteritis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.